Webcast ImageWebcast
Chromadex Corp at the 11th Annual LD Micro Main Event (Replay)
12/05/18 at 4:30 p.m. PT
Chromadex Corp at the 11th Annual LD Micro Main Event
Wednesday, December 5, 2018 4:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

More »
Stock Quote
Change (%) Stock is Down 0.06 (1.86%)
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
11/28/18ChromaDex to Present at the 11th Annual LD Micro Main Event
LOS ANGELES, Nov. 28, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Co-Founder & Executive Chairman, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The ChromaDex management team is scheduled to present on Wed., Dec. 5, 2018, at 4:30 p.m. PST.  ChromaDex management will also attend one-on-one meetings with... 
Printer Friendly Version
11/20/18New TRU NIAGEN® Stick Packs Target New Audiences and Consumer Needs
ChromaDex expands TRU NIAGEN® product line, offering single-serving stick packs for on-the-go consumers and athletes LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of TRU NIAGEN stick packs, offering a new delivery method of its revolutionary nicotinamide riboside ingredient to promote cellular energy and repair. The stick packs, which each provide 300mg nicotinamide riboside mixed with fiber source inulin (chicory root extract), wil... 
Printer Friendly Version
11/07/18ChromaDex Corporation Reports Third Quarter 2018 Financial Results
- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million - Third Quarter 2018 Highlights vs. Third Quarter 2017 Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%; TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60% Gross profit as a percentage of net sales improved by 580 basis points to 53.7%; Launched TRU NIAGEN PRO (60ct, 300mg per capsule), the highest dose of NR in a single capsule; Earned certification from NSF International Ce... 
Printer Friendly Version
What's New
December 2018 Investor Presentation PDF
ChromaDex Investor FAQs Third Quarter 2018 PDF
Q3 2018 Earnings Presentation PDF
2018 Q3 Quarterly Report on Form 10Q PDF
September 2018 Investor Presentation PDF
July 2018 Investor Presentation PDF
2018 Proxy Statement  PDF
2017 Annual Report on Form 10-K PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.